MarketScreener Homepage > Equities > Nasdaq > Seagen Inc. SGEN

Report

Delayed Nasdaq - 02/26 04:00:01 pm
151.11	USD		+0.68%

02/24

SEAGEN : to Present at the Cowen 41st Annual Healthcare Conference

02/19

ASTELLAS PHARMA : and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV in Locally Advanced or Metastatic Urothelial Cancer

02/18

INSIDER TRENDS : Seagen Insider Reports Option Conversion Extending 90-Day Buying Trend

Summary

Quotes 5-day view Delayed Quote.

Delayed Nasdaq

02/22/2021	02/23/2021	02/24/2021	02/25/2021	02/26/2021	Date
157.58(c)	157.03(c)	155.02(c)	150.09(c)	151.11(c)	Last
865 379	1 218 028	1 199 818	1 022 564	1 698 964	Volume
-0.11%	-0.35%	-1.28%	-3.18%	+0.68%	Change

More quotes

Financials (USD)

Sales 2021	1 504 M - -
Net income 2021	-393 M - -
Net cash position 2021	2 025 M - -
P/E ratio 2021	-69,9x
Yield 2021	-

Sales 2022	2 273 M - -
Net income 2022	89,2 M - -
Net cash position 2022	2 456 M - -
P/E ratio 2022	351x
Yield 2022	-

Capitalization	27 376 M 27 376 M -
EV / Sales 2021	16,9x
EV / Sales 2022	11,0x
Nbr of Employees	2 092
Free-Float	99,4%

More Financials

Company

Seagen Inc., formerly Seattle Genetics, Inc., is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company is commercializing ADCETRIS or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV...

Sector

Biotechnology & Medical Research

Calendar

03/01 | 02:40pm

Presentation

More about the company

Notations Surperformance© of Seagen Inc.

Trading Rating :

Investor Rating :

More Ratings

All news about SEAGEN INC.

02/24	SEAGEN : to Present at the Cowen 41st Annual Healthcare Conference	BU
02/19	ASTELLAS PHARMA : and Seagen Announce Submission of Two Supplemental Biologics L..	AQ
02/18	INSIDER TRENDS : Seagen Insider Reports Option Conversion Extending 90-Day Buyin..	MT
02/18	SEAGEN : Astellas Seek FDA Nod for Two Supplemental Applications For Cancer Drug	MT
02/18	SEAGEN : and Astellas Announce Submission of Two Supplemental Biologics License ..	BU
02/16	SEAGEN : RBC Capital Adjusts Seagen's Price Target to $169 From $186, Maintains ..	MT
02/15	SEAGEN : European Commission Approves Seagen's TUKYSA for the Treatment of Patie..	AQ
02/15	SEAGEN : and Astellas Announce Phase 3 Trial Results Demonstrating Survival Adva..	AQ
02/15	ASTELLAS PHARMA : and Seagen Announce Presentation of Results from PADCEV Pivota..	AQ
02/12	SEAGEN : and Astellas Announce Phase 3 Trial Results Demonstrating Survival Adva..	BU
02/12	SEAGEN : and Astellas Announce Presentation of Results from PADCEV® (enfortumab ..	BU
02/12	SEAGEN : Barclays Adjusts Seagen PT to $168 From $177, Maintains Equal Weight Ra..	MT
02/12	SEAGEN : JP Morgan Adjusts Price Target for Seagen to $177 From $182, Maintains ..	MT
02/12	SEAGEN : Goldman Sachs Adjusts Seagen's Price Target to $242 From $247, Maintain..	MT
02/12	SEAGEN : Piper Sandler Adjusts Price Target on Seagen to $170 From $175, Maintai..	MT

More news

News in other languages on SEAGEN INC.

2020	US-Konzern Merck & Co übernimmt Krebsforscher Velosbio
2020	SEAGEN INC. : Veröffentlichung des Quartalsergebnisses
2020	SEAGEN INC. : publication des résultats trimestriels
2020	10 Biotechs qui font parler d'elles
2020	Aktien New York Schluss: Übernahmen bescheren starken Wochenauftakt

More news

Analyst Recommendations on SEAGEN INC.

02/16	SEAGEN : RBC Capital Adjusts Seagen's Price Target to $169 From $186, Maintains ..	MT
02/12	SEAGEN : Barclays Adjusts Seagen PT to $168 From $177, Maintains Equal Weight Ra..	MT
02/12	SEAGEN : JP Morgan Adjusts Price Target for Seagen to $177 From $182, Maintains ..	MT

More recommendations

Provided by Scoopnest.com

Analysis

Wall Street closes broadly higher on deal news, vaccine hopes

More Must read

Chart SEAGEN INC.

Duration : Period :

Seagen Inc. Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends SEAGEN INC.

	Short Term	Mid-Term	Long Term
Trends	Bearish	Neutral	Bullish

Technical analysis

Income Statement Evolution

More Financials

Consensus

Sell

Buy

Mean consensus	OUTPERFORM
Number of Analysts	19
Average target price	190,76 $
Last Close Price	151,11 $
Spread / Highest target	68,1%
Spread / Average Target	26,2%
Spread / Lowest Target	-8,68%

Consensus

EPS Revisions

More Estimates Revisions

Managers and Directors

Name	Title
Clay B. Siegall	Chairman, President & Chief Executive Officer
Todd E. Simpson	Chief Financial Officer
Vaughn B. Himes	Chief Technical Officer
Robert J. Lechleider	Senior Vice President-Clinical Development
Roger D. Dansey	Chief Medical Officer

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

SEAGEN INC.	-13.72%	27 376



MODERNA, INC.	48.19%	61 888
LONZA GROUP AG	0.88%	46 924
IQVIA HOLDINGS INC.	7.60%	36 971
CELLTRION, INC.	-17.13%	35 993
HANGZHOU TIGERMED CONSULTING CO.,LTD	-13.01%	18 684

More Results